Player FM 앱으로 오프라인으로 전환하세요!
01_02 Latest and greatest in metastatic colon cancer – mAbs, MSI status, sidedness and controversies
Manage episode 324500957 series 3335024
1. Background on molecular targeted agents
2. VEGF-inhibitors
3. EGFR inhibition
4. Left vs Right sided colon cancer
5. MSI-H/dMMR status
Citations
As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com
DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.
Uptodate.com Waltham, MA: Wolters Kluwer.
Some highlighted references recommended to read related to this specific episode:
1. Botrel TEA et al. BMC Cancer. 2016;16(1):1-19. doi:10.1186/S12885-016-2734-Y/FIGURES/5
2. Deng T et al. Medical Oncol 2013 30:4. 2013;30(4):1-5. doi:10.1007/S12032-013-0752-Z
3. Hurwitz H et al. NEJM. 2009;350(23):2335-2342. doi:10.1056/NEJMOA032691
4. Booth CM, Goodman AM. Nature Rev Clinl Oncol 2021 18:11. 2021;18(11):673-674. doi:10.1038/s41571-021-00550-9
5. Booth C. J Clin Oncol. 2008;26(28):4693-4694. doi:10.1200/JCO.2008.18.8060
6. Saltz LB et al. J Clin Oncol. 2008;26(12):2013-2019. doi:10.1200/JCO.2007.14.9930
7. Stathopoulos GP et al. Oncology. 2010;78(5-6):376-381. doi:10.1159/000320520
8. Tang W et al. J Clin Oncol. 2020;38(27):3175-3184. doi:10.1200/JCO.20.00174
9. Giantonio BJ et al. J Clin Oncol. 2007;25(12):1539-1544. doi:10.1200/JCO.2006.09.6305
10. van Cutsem E et al. NEJM. 2009;360(14):1408-1417.
11. Cutsem E van, et al. J Clin Oncol. doi:10.1200/JCO.2010.28.15_SUPPL.3570
12. Bokemeyer C et al. Eur J Cancer. 2012;48(10):1466-1475. doi:10.1016/J.EJCA.2012.02.057
13. Tejpar S et al. JAMA Oncol. 2017;3(2):194-201. doi:10.1001/JAMAONCOL.2016.3797
14. Venook AP et al. JAMA. 2017;317(23):2392-2401. doi:10.1001/JAMA.2017.7105
15. Maughan TS et al. The Lancet. 2011;377(9783):2103-2114
16. Lenz HJ et al. J Clin Oncol. 2019;37(22):1876-1885. doi:10.1200/JCO.18.02258
17. Venook A et al. Ann Oncology. 2014;25(2):ii112. doi:10.1093/ANNONC/MDU193.19
18. Shiu KK et al. J Clin Oncol https://doi.org/101200/JCO2021393_suppl6. 2021;39(3_suppl):6-6. doi:10.1200/JCO.2021.39.3_SUPPL.6
19. André T et al. NEJM 2020;383(23):2207-2218.
20. Jonker DJ al. NEJM. 2009;2(11):2040-2048. doi:10.1056/NEJMOA071834
21. Brulé SY et al. Eur J Cancer. 2015;51(11):1405-1414. doi:10.1016/J.EJCA.2015.03.015
22. Tol J et al. NEJM. 2009;360(6):563-572.
Disclosures
Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.
49 에피소드
01_02 Latest and greatest in metastatic colon cancer – mAbs, MSI status, sidedness and controversies
Talking About Tumors with Ryann and Ryan - A medical oncology podcast
Manage episode 324500957 series 3335024
1. Background on molecular targeted agents
2. VEGF-inhibitors
3. EGFR inhibition
4. Left vs Right sided colon cancer
5. MSI-H/dMMR status
Citations
As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com
DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.
Uptodate.com Waltham, MA: Wolters Kluwer.
Some highlighted references recommended to read related to this specific episode:
1. Botrel TEA et al. BMC Cancer. 2016;16(1):1-19. doi:10.1186/S12885-016-2734-Y/FIGURES/5
2. Deng T et al. Medical Oncol 2013 30:4. 2013;30(4):1-5. doi:10.1007/S12032-013-0752-Z
3. Hurwitz H et al. NEJM. 2009;350(23):2335-2342. doi:10.1056/NEJMOA032691
4. Booth CM, Goodman AM. Nature Rev Clinl Oncol 2021 18:11. 2021;18(11):673-674. doi:10.1038/s41571-021-00550-9
5. Booth C. J Clin Oncol. 2008;26(28):4693-4694. doi:10.1200/JCO.2008.18.8060
6. Saltz LB et al. J Clin Oncol. 2008;26(12):2013-2019. doi:10.1200/JCO.2007.14.9930
7. Stathopoulos GP et al. Oncology. 2010;78(5-6):376-381. doi:10.1159/000320520
8. Tang W et al. J Clin Oncol. 2020;38(27):3175-3184. doi:10.1200/JCO.20.00174
9. Giantonio BJ et al. J Clin Oncol. 2007;25(12):1539-1544. doi:10.1200/JCO.2006.09.6305
10. van Cutsem E et al. NEJM. 2009;360(14):1408-1417.
11. Cutsem E van, et al. J Clin Oncol. doi:10.1200/JCO.2010.28.15_SUPPL.3570
12. Bokemeyer C et al. Eur J Cancer. 2012;48(10):1466-1475. doi:10.1016/J.EJCA.2012.02.057
13. Tejpar S et al. JAMA Oncol. 2017;3(2):194-201. doi:10.1001/JAMAONCOL.2016.3797
14. Venook AP et al. JAMA. 2017;317(23):2392-2401. doi:10.1001/JAMA.2017.7105
15. Maughan TS et al. The Lancet. 2011;377(9783):2103-2114
16. Lenz HJ et al. J Clin Oncol. 2019;37(22):1876-1885. doi:10.1200/JCO.18.02258
17. Venook A et al. Ann Oncology. 2014;25(2):ii112. doi:10.1093/ANNONC/MDU193.19
18. Shiu KK et al. J Clin Oncol https://doi.org/101200/JCO2021393_suppl6. 2021;39(3_suppl):6-6. doi:10.1200/JCO.2021.39.3_SUPPL.6
19. André T et al. NEJM 2020;383(23):2207-2218.
20. Jonker DJ al. NEJM. 2009;2(11):2040-2048. doi:10.1056/NEJMOA071834
21. Brulé SY et al. Eur J Cancer. 2015;51(11):1405-1414. doi:10.1016/J.EJCA.2015.03.015
22. Tol J et al. NEJM. 2009;360(6):563-572.
Disclosures
Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.
49 에피소드
Όλα τα επεισόδια
×플레이어 FM에 오신것을 환영합니다!
플레이어 FM은 웹에서 고품질 팟캐스트를 검색하여 지금 바로 즐길 수 있도록 합니다. 최고의 팟캐스트 앱이며 Android, iPhone 및 웹에서도 작동합니다. 장치 간 구독 동기화를 위해 가입하세요.